aTyr Pharma to Present at the LD Micro Main Event XVII in October
aTyr Pharma, a clinical stage biotech company developing medicines from its tRNA synthetase platform, has announced its participation in the 17th Annual LD Micro Main Event. The event is scheduled for October 28-30, 2024, in Los Angeles, CA.
Dr. Sanjay S. Shukla, President and CEO of aTyr Pharma, will present a corporate overview on Tuesday, October 29, 2024, at 9:00am PDT at the Luxe Sunset Boulevard Hotel. The three-day event will feature approximately 150 companies presenting in half-hour increments and attending private meetings with investors.
Interested parties can view aTyr's presentation online and request meetings with management by contacting registration@ldmicro.com. This event provides an opportunity for aTyr Pharma to showcase its progress in developing first-in-class medicines to potential investors and industry professionals.
aTyr Pharma, un'azienda biotecnologica in fase clinica che sviluppa farmaci dalla propria piattaforma di tRNA sintetasi, ha annunciato la sua partecipazione al 17° Annual LD Micro Main Event. L'evento è programmato per 28-30 ottobre 2024, a Los Angeles, CA.
Il Dr. Sanjay S. Shukla, Presidente e CEO di aTyr Pharma, presenterà una panoramica aziendale martedì 29 ottobre 2024, alle 9:00 PDT presso il Luxe Sunset Boulevard Hotel. L'evento di tre giorni presenterà circa 150 aziende che si esibiranno in sessioni di mezz'ora e parteciperanno a incontri privati con gli investitori.
Le parti interessate possono visualizzare la presentazione di aTyr online e richiedere incontri con la direzione contattando registration@ldmicro.com. Questo evento offre un'opportunità per aTyr Pharma di mostrare i propri progressi nello sviluppo di farmaci innovativi a potenziali investitori e professionisti del settore.
aTyr Pharma, una empresa biotecnológica en etapa clínica que desarrolla medicamentos a partir de su plataforma de sintetasas de tRNA, ha anunciado su participación en el 17° Evento Principal Anual de LD Micro. El evento está programado para 28-30 de octubre de 2024, en Los Ángeles, CA.
El Dr. Sanjay S. Shukla, Presidente y CEO de aTyr Pharma, presentará una visión general de la empresa el martes 29 de octubre de 2024, a las 9:00 a.m. PDT en el Luxe Sunset Boulevard Hotel. El evento de tres días contará con aproximadamente 150 empresas presentando en incrementos de media hora y asistiendo a reuniones privadas con inversores.
Las partes interesadas pueden ver la presentación de aTyr en línea y solicitar reuniones con la dirección contactando a registration@ldmicro.com. Este evento brinda la oportunidad a aTyr Pharma de mostrar su progreso en el desarrollo de medicamentos de primera clase a posibles inversores y profesionales de la industria.
aTyr Pharma는 tRNA 합성효소 플랫폼을 기반으로 의약품을 개발하는 임상 단계의 생명공학 회사로서, 제17회 LD 마이크로 메인 이벤트에 참여한다고 발표했습니다. 이 행사는 2024년 10월 28일부터 30일까지, 로스앤젤레스, CA에서 열릴 예정입니다.
aTyr Pharma의 사장 겸 CEO인 Dr. Sanjay S. Shukla는 2024년 10월 29일 화요일, 오전 9:00 PDT에 Luxe Sunset Boulevard Hotel에서 회사 개요를 발표할 것입니다. 이 3일간의 행사에서는 약 150개 회사가 30분 간격으로 발표하고 투자자들과의 비공식 회의에 참석하게 됩니다.
관심 있는 분들은 aTyr의 발표를 온라인에서 시청하고, registration@ldmicro.com으로 연락하여 경영진과의 회의를 요청할 수 있습니다. 이 행사는 aTyr Pharma가 혁신적인 의약품 개발에서의 진전을 잠재 투자자 및 업계 전문가들에게 보여줄 수 있는 기회를 제공합니다.
aTyr Pharma, une entreprise biopharmaceutique en phase clinique développant des médicaments à partir de sa plateforme de synthétases d'ARNt, a annoncé sa participation au 17ème Événement Principal Annuel de LD Micro. L'événement est prévu du 28 au 30 octobre 2024, à Los Angeles, CA.
Dr. Sanjay S. Shukla, Président et PDG de aTyr Pharma, présentera une vue d'ensemble de l'entreprise le mardi 29 octobre 2024, à 9h00 PDT au Luxe Sunset Boulevard Hotel. L'événement de trois jours présentera environ 150 entreprises avec des présentations de 30 minutes et des réunions privées avec des investisseurs.
Les parties intéressées peuvent visionner la présentation de aTyr en ligne et demander des réunions avec la direction en contactant registration@ldmicro.com. Cet événement offre à aTyr Pharma l'occasion de montrer ses progrès dans le développement de médicaments de premier ordre à des investisseurs potentiels et des professionnels de l'industrie.
aTyr Pharma, ein biopharmazeutisches Unternehmen in der klinischen Phase, das Medikamente aus seiner tRNA-Synthetase-Plattform entwickelt, hat seine Teilnahme an der 17. jährlichen LD Micro Hauptveranstaltung angekündigt. Die Veranstaltung ist für 28.-30. Oktober 2024 in Los Angeles, CA, geplant.
Dr. Sanjay S. Shukla, Präsident und CEO von aTyr Pharma, wird am Dienstag, den 29. Oktober 2024, um 9:00 Uhr PDT im Luxe Sunset Boulevard Hotel eine Unternehmensübersicht präsentieren. Während der dreitägigen Veranstaltung werden etwa 150 Unternehmen Präsentationen in halbstündlichen Abständen halten und an privaten Meetings mit Investoren teilnehmen.
Interessierte Parteien können aTyrs Präsentation online ansehen und durch Kontaktaufnahme mit registration@ldmicro.com Meetings mit der Geschäftsführung anfragen. Diese Veranstaltung bietet aTyr Pharma die Möglichkeit, den potenziellen Investoren und Fachleuten aus der Branche ihre Fortschritte bei der Entwicklung innovativer Medikamente vorzustellen.
- None.
- None.
San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 17th Annual LD Micro Main Event, which is scheduled to take place October 28 – 30, 2024, in Los Angeles, CA.
Details of the presentation appear below:
Conference: LD Micro Main Event XVII
Date: Tuesday, October 29, 2024
Time: 9:00am PDT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
The three-day event will feature around 150 companies, presenting in half-hour increments, and attending private meetings with investors. aTy's presentation will be available to view here. For more information and to request a meeting with management, please contact registration@ldmicro.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226443
FAQ
When and where will aTyr Pharma (ATYR) present at the LD Micro Main Event XVII?
Who will be presenting the corporate overview for aTyr Pharma (ATYR) at the LD Micro Main Event?
How can investors view aTyr Pharma's (ATYR) presentation at the LD Micro Main Event?
How many companies are expected to present at the LD Micro Main Event XVII in October 2024?
How can investors request a meeting with aTyr Pharma (ATYR) management during the LD Micro Main Event?
